Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Navigo Proteins GmbH is currently addressing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active cases are handled by 4 distinct examiners, showing that each pending matter is being reviewed by a different official. Despite the variety of examiners, the portfolio is contained within 3 distinct art units, suggesting some level of thematic consistency in the examination environment. This structure requires the company to manage multiple prosecution timelines simultaneously while adapting to the specific requirements of several different individuals.
The busiest examiner identified is OGUNTADE, ELIZABETH BISOLA, who is responsible for 1 pending office action. With 4 pending actions spread across 3 art units, the company's success in the biotechnology sector depends on meeting the diverse expectations of the assigned examiners. Because no single examiner manages more than 1 pending action, the portfolio's progress is not overly dependent on any one individual's discretion. This distribution of 4 actions across 4 examiners ensures that the company's patenting strategy remains diversified across the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 0.0% | +0.0% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 16d |
| 18575743 | Affinity ligands for the purification and detection of ubiquitin muteins | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 85d overdue |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 16d |
| 18012284 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575743 | Affinity ligands for the purification and detection of ubiquitin muteins | OGUNTADE, ELIZABETH BISOLA | — | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18036142 | NEW TYPE II COLLAGEN BINDING PROTEINS | PUTTLITZ, KARL J | 1646 | §112DP | Final Rejection | 85d overdue | Pending | May 09, 2023 |
| 18016436 | SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS | DAHLE, CHUN WU | 1641 | §102§112 | Final Rejection | 16d | Pending | Jan 16, 2023 |
| 18012284 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | SALVOZA, M FRANCO G | 1672 | §112 | Non-Final OA | — | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial